Cardio3 BioSciences announces participation at the 32nd Annual JP Morgan Healthcare Conference in San Francisco

Cardio3 BioSciences announces participation at the 32nd Annual JP Morgan Healthcare Conference in San Francisco

Cardio3 BioSciences raises € 4.0 million in non-dilutive funding from the Walloon Region

Cardio3 BioSciences raises € 4.0 million in non-dilutive funding from the Walloon Region

Cardio3 BioSciences C-Cath® Article Published in Circulation Cardiovascular Interventions

Cardio3 BioSciences C-Cath® Article Published in Circulation Cardiovascular Interventions

Cardio3 BioSciences Partner and Exploitation Manager of a Eur 6.8 Million FP7 Research Grant for AMCARE Program

Cardio3 BioSciences Partner and Exploitation Manager of a Eur 6.8 Million FP7 Research Grant for AMCARE Program

Cardio3 BioSciences Partner and Exploitation Manager of a Eur 4.5 Million FP7 Research Grant

Cardio3 BioSciences Partner and Exploitation Manager of a Eur 4.5 Million FP7 Research Grant

Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Wallonia

Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Wallonia

Cardio3 Biosciences announces Q3 2013 business update and authorization to enroll patients in Poland in its chart-1 Phase III Clinical Trial

Cardio3 Biosciences announces Q3 2013 business update and authorization to enroll patients in Poland in its chart-1 Phase III Clinical Trial

Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Walloon Brabant

Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Walloon Brabant

Cardio3 BioSciences to participate at the KBC Securities Benelux Biotech Healthcare Conference in New York on November 13 & 14

Cardio3 BioSciences to participate at the KBC Securities Benelux Biotech Healthcare Conference in New York on November 13 & 14

Cardio3 BioSciences strengthens management team by appointing Dr. Gaëtane Metz as Chief Operating Officer

Cardio3 BioSciences strengthens management team by appointing Dr. Gaëtane Metz as Chief Operating Officer

Cardio3 BioSciences Receives Authorization to Enroll Patients in Italy in its Phase III Clinical Trial CHART-1

Cardio3 BioSciences Receives Authorization to Enroll Patients in Italy in its Phase III Clinical Trial CHART-1

Cardio3 BioSciences Receives Authorization to Begin World’s First Phase III Clinical Trial in Regenerative Medicine for Heart Failure in Spain

Cardio3 BioSciences Receives Authorization to Begin World’s First Phase III Clinical Trial in Regenerative Medicine for Heart Failure in Spain